Is there renewed enthusiasm on the public markets for biotech companies following the uptick in IPOs seen at the start of 2024 and in the late summer and autumn? What advice would you give to biotechs considering an IPO listing? Are there key traits that define successful biotech IPOs, or red flags that signal less successful ones? How do biotech IPO trends fit in the broader IPO market context, and what can we expect to see in 2025?
For an insight into these and other important points, listen to James Waldron’s interview to Adam Farlow, Global Head of Baker McKenzie’s Capital Markets Practice Group.
The interview was featured in Fierce Biotech on 6 December 2024, and is available here: What can we learn from 2024’s biotech IPOs? | Fierce Biotech
